Skip to main content
. 2020 Aug 27;11:2000. doi: 10.3389/fimmu.2020.02000

Figure 2.

Figure 2

De novo DR/DQ DSA-free survival curves. (A) De novo DR/DQ DSA-free survival by eplet mismatch. Kaplan-Meier de novo DR/DQ-free survival curves and Wilcoxon test show significant difference (p < 0.0001) between epitope mismatches 1–13 and 14–67. Thick dotted line, thin black line and thick black line indicate DSA-free survival (months after transplantation) of groups with eplet mismatches 0, 1–13, and 14–67, respectively. (B) De novo DR/DQ DSA-free survival by PIRCHE score. Kaplan-Meier de novo DR/DQ-free survival curves and Wilcoxon test show significant difference (p < 0.0001) between PIRCHE scores 1–175 and 176–763. Thick dotted line, thin black line and thick black line indicate DSA-free survival (months after transplantation) of groups with PIRCHE scores 0, 1–175, and 176–763, respectively. (C) De novo DR/DQ DSA-free survival by both eplet mismatch and PIRCHE score. Subgroup analysis by Kaplan-Meier de novo DR/DQ-free survival curves and Wilcoxon test shows significant differences between low and high PIRCHE scores among patients with low eplet mismatches (p = 0.0304) and high eplet mismatches (p = 0.0462). Thin dotted line, thin black line, thick dotted line and thick black line indicate DSA-free survival (months after transplantation) of groups including low eplet + low PIRCHE, low eplet + high PIRCHE, high eplet + low PIRCHE, and high eplet + high PIRCHE, respectively. Low eplet mismatches = 0–13; high eplet mismatches = 14–67; low PIRCHE scores = 0–175; high PIRCHE scores = 176–763.